Home / Deep Research / CHRNA1-Associated Fetal Hypo-akinesia Disorder of Prenatal Onset

CHRNA1-Associated Fetal Hypo-akinesia Disorder of Prenatal Onset

Question

Codex MONDO:0009668 Model: gpt-5

Question

Review the evidence base for a new disorder entry modeling CHRNA1-associated fetal hypo-akinesia disorder of prenatal onset, with attention to whether the prenatal-lethal CHRNA1 presentation is best treated as a lethal multiple pterygium / fetal akinesia disease anchor and whether the phenotype section is supported by exact PMID-backed evidence.

Selected PMID-backed evidence

  • PMID:18252226 Foundational CHRNA1 paper showing that homozygous nonsense mutations in CHRNA1 can be lethal and that severe disruption of fetal AChR function produces a lethal multiple pterygium / fetal hypokinesia phenotype.
  • PMID:36092864 Direct CHRNA1 case report with recurrent affected pregnancies, compound heterozygous variants, reduced fetal movement, edema, fetal neck cystoma, and joint contractures.
  • PMID:26932181 LMPS abstract with exact wording for pterygium, severe arthrogryposis, foetal hydrops, and cystic hygroma, useful for phenotype evidence where the core syndrome morphology is shared across genetic causes.
  • PMID:3344777 FADS abstract with exact wording for micrognathia and pulmonary hypoplasia as downstream consequences of fetal akinesia.

Curation decisions

  • Kept the disease entry provisionally grounded to MONDO:0009668 lethal multiple pterygium syndrome because MONDO NTR #8449 is still pending in the local MONDO release.
  • Treated the disorder as the prenatal-lethal loss-of-function end of the CHRNA1 congenital myasthenic syndrome spectrum rather than conflating it with postnatal fast- or slow-channel CHRNA1 CMS phenotypes.
  • Used exact abstract-backed phenotype evidence for all structured phenotypes.
  • Allowed broader LMPS/FADS literature to support phenotype morphology when the CHRNA1-specific literature was sufficient for disease causality but sparse for every individual prenatal feature.